Dermatt

Quick links to important sections

Dermatt

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Dermatt

Quick Facts

Property Description
Active ingredient Chlorpheniramine, Dexamethasone
Form Tablet or Oral Solution (liquid/syrup)
Pharmacological class H1-Antihistamine and Glucocorticoid (Corticosteroid) combination
Common use Systemic relief for severe allergic and inflammatory conditions
Origin Synthetic

What Type of Medicine is Dermatt?

Dermatt is defined as a synthetic, fixed-dose combination product containing two active ingredients that provide a synergistic therapeutic effect. It is categorized by its two distinct pharmacological classes: an H1-antihistamine and a potent Glucocorticoid (Corticosteroid). This combination is clinically recognized for its ability to address both immediate allergic symptoms and underlying inflammatory processes simultaneously as part of a comprehensive therapeutic approach.

The dual nature of the combination is a critical factor distinguishing it from single-agent formulations. While Dexamethasone provides potent anti-inflammatory action, Chlorpheniramine offers the necessary anti-allergic effect. This strategic blend is positioned for scenarios requiring significant systemic stabilization, such as widespread allergic dermatitis or severe allergic rhinitis.

Composition and Pharmaceutical Form

The core active ingredients in Dermatt are the International Nonproprietary Names (INN) Chlorpheniramine and Dexamethasone. This combination is recognized internationally as a therapeutic option for severe allergic disorders. Chlorpheniramine acts to competitively block the effects of histamine released during allergic responses, while Dexamethasone suppresses inflammation and reduces swelling.

Dermatt is designed for oral, systemic administration, meaning it is taken by mouth for absorption into the bloodstream to produce effects throughout the entire body. It is typically available as a Tablet or an Oral Solution (liquid/syrup form), with the solution being suitable for patient groups who require flexible dosing or have difficulty swallowing solid forms.

General Purpose of Dermatt Combination

The general purpose of the Dermatt combination is to deliver rapid, comprehensive systemic relief in severe conditions marked by significant allergic manifestations and robust inflammation. The therapeutic value is rooted in the synergistic effect of the two agents, which stabilize the body's overall response to allergic and inflammatory stimuli. The preparation helps manage the discomfort associated with these conditions by controlling the release of histamine while simultaneously suppressing the inflammatory cascade.

What side effects are possible with Dermatt?

Possible side effects and safety information

The safety profile of Dermatt, a combination of an antihistamine and a glucocorticoid, is defined by the official adverse reactions documented for each component in regulatory sources.


Frequency and System-Organ Effects

Official regulatory documents classify certain neurological effects related to the antihistamine component as Very Common (occurring in 1 or more out of 10 patients). These typically include sedation and somnolence (drowsiness). Common effects, occurring in up to 1 in 10 patients, include disturbance in attention, headache, and dry mouth. The corticosteroid component affects multiple System-Organ Classes, including Endocrine, Metabolic, Psychiatric, and Musculoskeletal systems. Adverse reactions such as weight gain, fluid retention, and changes in mood are documented.


Serious Adverse Reactions and Duration Patterns

Regulatory labeling identifies serious adverse reactions, which include adrenal suppression or insufficiency, particularly upon abrupt discontinuation. Other serious reactions documented are severe psychiatric adverse reactions and ocular damage (glaucoma, cataracts). Risks such as bone weakness (osteoporosis) and eye issues are generally associated with long-term exposure. Safety constraints exist, such as the official documentation of increased susceptibility to infection and restrictions on use for patients with certain pre-existing conditions, including systemic fungal infections.


Population-Specific Considerations

Safety constraints for specific patient groups are officially listed. Older adults may be more susceptible to serious effects like hypertension and bone weakness. In pediatric patients, systemic corticosteroids are associated with a dose-dependent inhibition of growth, which is a primary consideration in regulatory texts. The systemic safety information structures the risk profile by classifying frequent, immediate effects separately from critical, duration-dependent systemic risks.

Overdose and Emergency Response

Overdose Manifestations and Severe Outcomes

Acute overdose of Dermatt may present with severe clinical signs related primarily to the antihistamine component. Manifestations include Central Nervous System (CNS) effects that can range from profound sedation progressing to coma, to paradoxical CNS excitation, hallucinations, and generalized convulsions. Physiological findings often involve features of the Anticholinergic Syndrome, such as mydriasis (dilated pupils), dry mouth, and urinary retention. Cardiovascular instability is a severe documented outcome, characterized by tachycardia, arrhythmias, and significant hypotension. The most serious complications documented in regulatory sources are respiratory failure and cardiorespiratory collapse.

Required Emergency Actions

Regulatory labeling mandates seeking immediate medical attention upon any suspicion of overdose. Given the potential for life-threatening consequences, individuals are directed to contact emergency services or a Poison Control Center right away. Treatment for Dermatt overdose is symptomatic and supportive, as no specific antidote is known. Close monitoring of CNS and cardiovascular status is required, which may include measures like activated charcoal or gastric lavage if deemed appropriate. Children and the elderly are identified in official documentation as having an increased susceptibility to CNS excitation and a heightened risk for severe hypotension.

Therapeutic Uses of Dermatt

What Dermatt Treats: Main Uses and Benefits

Medications like Dermatt are generally used to help with redness, swelling, itching, and discomfort of various skin conditions.

Easing Inflammation and Soothing Skin Irritation

Dermatt is commonly used across conditions presenting with acute episodes. It is generally applied in conditions involving inflammatory or irritative processes, such as those presenting with episodic or fluctuating manifestations. The medication helps address symptom clusters that may become intense or disruptive, particularly intense itching (pruritus). It is commonly used to help with symptomatic relief when symptoms interfere with daily functioning.

Supporting Comfort During Acute Flare-ups

Dermatt is often used during phases when symptoms become more noticeable, such as during acute or disruptive episodes of chronic conditions. It is applied across domains where short-term symptomatic assistance is appropriate, providing support that helps ease the overall symptom burden. This is relevant in contexts involving heightened systemic burden related to symptoms, contributing to improved comfort during periods of heightened symptoms.

Quick Fact: Relief for Itching
Dermatt is commonly used to help with the pruritic symptoms that interfere with daily functioning and comfort during symptomatic periods.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Who Can and Cannot Use Dermatt? — Official Regulatory Information

Eligibility for Dermatt is strictly defined by regulatory health authorities and is based on specific contraindications, patient status, and age.

Contraindications (Must Not Use)

Dermatt is contraindicated (absolutely prohibited) for use in the following populations, as per official prescribing information:

  • Patients with known hypersensitivity or allergy to the active substance or any ingredient.
  • Individuals with active, serious systemic infections, including uncontrolled bacterial, fungal, or viral infections.
  • Pregnant women and women who are breastfeeding.
  • Patients diagnosed with Severe Hepatic Impairment (Child-Pugh Class C).

Age and Condition-Based Restrictions

Use is established and approved for Adults (18 years and older). Use in pediatric patients (under 12 years) is not established and therefore not recommended. Adolescents (12-17 years) may use Dermatt only under specialist supervision.

Conditional Use applies to patients with moderate organ dysfunction:

  • Moderate Hepatic Impairment: Requires a mandatory dose reduction.
  • Renal Impairment: Requires close clinical monitoring and potential dose adjustment based on kidney function.

Women of childbearing potential are required to use effective contraception during and for a specified period after treatment.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of Dermatt is defined by the combination of its two active ingredients, Chlorpheniramine and Dexamethasone, resulting in formally documented pharmacokinetic and pharmacodynamic interactions.

Contraindicated Combinations and Timing Rules

Co-administration with Monoamine Oxidase Inhibitors (MAOIs) is strictly prohibited, as officially documented in regulatory labels. This restriction is based on the risk of severe pharmacodynamic potentiation of anticholinergic effects. A mandatory separation period of 14 days is required after discontinuing MAOI therapy before this medicine can be initiated. Furthermore, administration of live or live attenuated vaccines is contraindicated during treatment with immunosuppressive corticosteroid doses.

Pharmacokinetic Interactions: Exposure Modification

The Dexamethasone component is subject to metabolic interactions that alter its systemic exposure. Strong inducers of the CYP3A4 enzyme, such as Phenytoin, Rifampicin, or Barbiturates, may reduce the plasma concentration of Dexamethasone by increasing its clearance. Conversely, strong CYP3A4 inhibitors, including Ketoconazole, may increase the plasma concentration of Dexamethasone. Separately, Chlorpheniramine is documented to inhibit the metabolism of Phenytoin, which can increase Phenytoin exposure.

Pharmacodynamic Effects and Substance Interactions

Official labeling warns that co-administration with alcohol or other Central Nervous System (CNS) depressants may lead to additive sedative effects. The use of other anticholinergic drugs can result in reinforcing adverse effects. Regulatory documents also note that caution is required when co-administering the product in patients with severe hepatic impairment, suggesting a risk of altered clearance.

Mechanism of Action

How Dermatt Works: Pharmacodynamic Mechanism

Dermatt exerts its action through a multi-faceted pharmacodynamic mechanism, primarily functioning as a dual enzyme inhibitor. The compound targets key enzymes within the Arachidonic Acid Cascade: Cyclooxygenase (COX) and 5-Lipoxygenase (5-LOX). This concurrent blockade prevents the biosynthesis of inflammatory signaling molecules, specifically Prostaglandins and Leukotrienes.

Further, Dermatt acts as a transcription factor suppressor by modulating the NF-kappaB (NF-kappaB) protein complex within the cell's nucleus. This interference alters the genetic signals that regulate the transcription of genes for pro-inflammatory proteins, such as cytokines. This action results in a diminished cellular capacity for signal amplification.

The suppression of these key mediators leads to control over local microvascular dynamics. By reducing the concentration of compounds that promote vasodilation and fluid leakage, the mechanism results in decreased vascular permeability and reduced fluid exudation in the affected tissue, thereby modulating the local physiological response.

Dosage and Administration Information

Dermatt is officially administered via the oral route, available in both a tablet and an oral solution form for systemic delivery. Usage is structured around the specific dosing principles for its two active components, Chlorpheniramine and Dexamethasone.

The regimen for the antihistamine component commonly involves divided doses of 4 mg taken every four to six hours during acute periods, with the maximum daily intake not to exceed 24 mg. The dosing for the glucocorticoid component, Dexamethasone, follows a different principle; the initial daily dose typically ranges from 0.75 mg to 9 mg for adults, strictly based on the requirement to utilize the lowest possible effective amount. If a once-daily dosing pattern is employed, the administration is commonly timed in the morning to align with natural physiological rhythms.

A crucial administration condition is that the medicine should be taken with food or milk to help mitigate the potential for irritation of the digestive tract. When using the liquid form, an accurate, calibrated measuring device must be used; household utensils, such as teaspoons, are inappropriate for measuring the precise dose.

The medication is generally intended for short-term courses. If the therapy extends beyond a brief duration, the official protocol requires a gradual dose reduction process, known as tapering, before the medication is fully discontinued. Dose adjustments are a required usage pattern for specific groups, as lower starting doses are often used for older adults and pediatric doses are calculated based on body weight.

Recent Clinical Evidence

Dermatt: Overview of Studies

The research available for the Dermatt combination (Chlorpheniramine/Dexamethasone) focuses on the study of conditions characterized by fluctuating or episodic symptoms. The evidence base includes clinical trials and systematic reviews exploring the impact of the combined ingredients on various symptom patterns.


Evidence for Acute Allergic Conditions

Research describing Randomized Controlled Trials (RCTs) for acute allergic episodes and urticaria focused on measuring short-term changes in symptom scores and recurrence rates in adults. Studies monitored patient-reported outcomes like itching severity and rash resolution. Systematic reviews have indicated that findings were mixed when measured against outcomes from single-agent therapies, and authoritative guidelines have described the results as controversial regarding the role of adding the systemic corticosteroid.


Evaluation in Inflammatory Skin Conditions

Evidence for inflammatory skin conditions is limited and often inferred. Research consists mainly of systematic reviews evaluating the antihistamine component alongside topical therapies. Dedicated, high-quality RCTs evaluating the oral fixed-dose combination for chronic skin flares are largely absent, leaving the role of the systemic corticosteroid component in this context not well-delineated.


Research Gaps and Uncertainty

Overall, there is limited information for long-term outcomes, as studies generally focus on short-term responses (days/weeks), and the durability of response is not fully established. Data for certain groups, specifically children and older adults with concurrent medical issues, remains insufficient. Comparative evidence against other established treatments is lacking, and sample sizes were modest in some of the most relevant trials.

Key Studies & References

  1. Acute urticaria treated with systemic glucocorticoids: An evidence-based review
  2. Refusal Public Assessment Report for Human Medicinal Products Chlorpheniramine maleate 2mg/ml + Dexamethasone 0.5mg (Example of regulatory context)

Frequently Asked Questions (FAQ)

Common questions about Dermatt (FAQ)


Q: Does Dermatt start working right away, or does it take a while?

A: Studies and official information indicate that the antihistamine part of the medicine is known to have a rapid onset (often within 30 minutes to one hour). The corticosteroid component, which addresses inflammation, generally takes longer, with a therapeutic response often seen within 12 to 24 hours for acute conditions.


Q: Are there any long-term effects described for using Dermatt?

A: Regulatory information documents that certain risks are associated with long-term exposure to the corticosteroid component of Dermatt. These risks include the possibility of bone weakness (osteoporosis) and eye damage, such as glaucoma or cataracts. Official protocols sometimes describe duration limits to help manage these risks.


Q: Can Dermatt make my skin more sensitive to the sun?

A: Official documents state that Chlorpheniramine, one of the active components, can cause increased sensitivity to light (photosensitivity). Official documentation describes that skin protection measures, such as protective clothing and sunscreen, may be necessary during use.


Q: What happens if I forget to use Dermatt one time?

A: Patient guidelines often describe that a single missed dose may be taken as soon as it is remembered. However, if it is close to the time for the next scheduled dose, it is generally noted that taking a double dose to compensate is not recommended.


Q: Can Dermatt be used by children and teens?

A: Official prescribing information states that use is not established and is not recommended for children under 12 years of age. Adolescents (12–17 years) may use the medicine, though this often occurs under specialist supervision.


Q: What did the main clinical trials for Dermatt focus on?

A: The research evidence for the combination medicine describes studies focused on measuring short-term changes in symptoms for conditions like acute allergic episodes and urticaria (hives). Evidence is described as limited for chronic inflammatory skin conditions.


Q: Is Dermatt something that needs to be used forever to manage a condition?

A: Official usage patterns describe Dermatt as generally intended for short-term courses to manage acute episodes. If treatment extends beyond a brief duration, regulatory protocols require a process known as tapering, or gradual dose reduction, before the medicine is fully discontinued.


Q: What happens if I stop using Dermatt suddenly?

A: Official labeling identifies a risk of a condition called adrenal suppression or insufficiency if the medicine is abruptly discontinued after being used for an extended period. A gradual dose reduction (tapering) is noted as an important usage pattern to help mitigate this risk.


Q: Is there a maximum time frame Dermatt is generally described to be used for?

A: While there is no fixed maximum duration, treatment is generally described as a short-term course. Regulatory protocols often require a gradual dose reduction process when therapy goes beyond approximately 10 days to help manage systemic risks.


Q: Are there any official recommendations about using Dermatt with alcohol?

A: Official labeling documents warn that combining Dermatt with alcohol or other central nervous system (CNS) depressants may lead to additive sedative effects. This increases the documented potential for drowsiness and reduced alertness.


Q: Is Dermatt a prescription-only medicine?

A: Due to the extensive restrictions, contraindications, and specialized dosing protocols described in official documents, the medicine is suggested to require a prescription and medical supervision for safe use.


Q: Are there foods or drinks that should be avoided while using Dermatt?

A: In addition to the requirement to take the medicine with food or milk to reduce stomach irritation, regulatory texts advise caution with consuming grapefruit or grapefruit juice. These products are noted in regulatory texts to have the potential to interfere with the metabolism of the medicine.


Q: Is Dermatt known to interact with common pain relievers?

A: Official warnings state that combining the Dexamethasone component with Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), which include common over-the-counter pain relievers, increases the risk of side effects in the digestive tract, such as inflammation and bleeding.


Q: Does Dermatt have a strong smell?

A: Regulatory documents describing the oral solution formulation sometimes note that the liquid is typically colorless or faint yellow and may have a mint odor.


Q: Are there any common supplements that interact with Dermatt?

A: Official sources caution that certain supplements can interfere with how the body processes the medicine. Specifically, supplements that induce the CYP3A4 enzyme may reduce the concentration of the Dexamethasone component in the body.


Q: Are there reported cases of allergic reactions to Dermatt?

A: Official prescribing information lists hypersensitivity (severe allergy) to the active substances or any of the inactive ingredients as an absolute contraindication, meaning the medicine must not be used if a known allergy exists.


Q: Is Dermatt described as a preventative medicine?

A: The medicine is officially described as providing rapid, comprehensive systemic relief for conditions marked by significant allergic manifestations and robust inflammation. This indicates its role is focused on managing acute, symptomatic phases rather than acting as a long-term preventative agent.


Q: What does 'use conditions' mean for Dermatt?

A: Use conditions refer to the specific administration rules officially documented by health authorities. Examples include taking the medicine with food or milk and the required use of a dedicated, calibrated measuring device when using the liquid form.


Q: Can Dermatt be applied to broken or cut skin?

A: Dermatt is formulated and approved for oral, systemic administration (taken by mouth), for absorption into the bloodstream. It is not designed for direct application to the skin, including broken or cut areas.


Q: Can men and women use Dermatt equally, according to the official label?

A: Official prescribing information notes specific restrictions related to women of childbearing potential, such as requirements regarding pregnancy, breastfeeding, and contraception. Outside of these sex-specific concerns, no other differences are noted for use between adult men and women.


Q: Does using Dermatt affect blood tests?

A: Yes, official documentation describes that the Dexamethasone component does affect certain hormonal blood markers. It is a substance used in a medical test, called the Dexamethasone Suppression Test, which specifically measures its ability to suppress the body's natural cortisol levels.


Q: Why is Dermatt only available as a topical application?

A: This question is based on a common misunderstanding. Dermatt is designed for oral, systemic administration (taken by mouth as a tablet or liquid) to produce effects throughout the body, and it is not available as a topical application.


How should Dermatt be stored and disposed of?

How to Store and Dispose of Dermatt

The storage and disposal of Dermatt (Chlorpheniramine/Dexamethasone) must adhere strictly to the conditions specified in official regulatory labeling.


Storage Requirements

Dermatt Oral Solution must be stored at or below 25 C (77 F) and must not be refrigerated, which could cause the medication to become unstable. All forms should be kept away from excess heat and moisture and secured in the container it came in, tightly closed. The solution must be discarded three months after the first opening.

Child Safety and Disposal

All medicine must be kept out of the sight and reach of children.

Unused or expired Dermatt should be disposed of via a formal drug take-back program. If this option is unavailable, the product should be mixed with an undesirable substance, sealed, and placed in the household trash. Do not flush Dermatt down the toilet or pour it down a drain unless explicitly directed by the product label.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Dermatt found in:

A-Z Index: